Exelixis EXEL Business Segments — Cost of goods sold

Similar metrics at other companies

MDGLReportable Segment — Cost of Product and Service Sold

$26.85M+495%

INSMReportable Segment — Cost of product revenues (excluding amortization of intangible assets)

$47.42M+123%

GMEDReportable Segment — Cost of sales (exclusive of amortization of intangibles)

$202.99M+22.0%

BBIOReportable Segment — Cost of Revenue

$9.94M+277%

MDGLReportable Segment — Cost of Sales

$18.12M+742%

NBIXReportable Segment — Cost of revenues

$13.8M+50.0%

Questions, answered.

What is Exelixis's business segments — cost of goods sold?

Exelixis (EXEL) reported business segments — cost of goods sold of $19.95M in Q1 2026.

How has Exelixis's business segments — cost of goods sold changed year-over-year?

Exelixis's business segments — cost of goods sold increased by 4.1% year-over-year, from $19.17M to $19.95M.

What is the long-term trend for Exelixis's business segments — cost of goods sold?

Over 3 years (2022 to 2025), Exelixis's business segments — cost of goods sold has grown at a 13.1% compound annual growth rate (CAGR), from $57.91M to $83.7M.

What does business segments — cost of goods sold mean?

The direct costs incurred to produce and supply the company's pharmaceutical products.

How do you interpret business segments — cost of goods sold?

A lower ratio relative to revenue suggests improved manufacturing efficiency or economies of scale.

How does business segments — cost of goods sold compare across companies?

Standard COGS metric; peers typically maintain low ratios due to high-margin nature of specialty oncology drugs.